Best CROs for Rare Disease & Orphan Drug Clinical Trials
Top-rated CRO for rare disease trials
IQVIA  CVC evidence score 85.0/10 — ranked #1 of 247 tracked vendors by CVC evidence data.
Based on verified criteria scores, review coverage, and studies managed in the CVC methodology. Compare the full list below.
Rare disease trials are fundamentally different from standard drug development. With patient populations sometimes numbering in the hundreds worldwide, sponsors need CROs with established rare disease networks, adaptive trial design expertise, and deep regulatory knowledge of orphan drug pathways.
Key Challenges in Rare Disease Trials
- Small patient populations ? Often fewer than 200 patients globally, requiring multinational site networks
- Geographic dispersion ? Patients and investigators spread across many countries and continents
- Novel endpoints ? Biomarker-driven or composite endpoints unique to each rare condition
- Natural history studies ? Often required as a baseline comparator when placebo arms are unethical
- Regulatory incentives ? Orphan drug designation, priority review vouchers, and accelerated assessment pathways
Selecting a Rare Disease CRO
When evaluating CROs for rare disease programmes, consider:
- Track record in specific rare disease therapeutic areas
- Established relationships with patient advocacy groups and rare disease registries
- Experience with adaptive and Bayesian trial designs suitable for small samples
- Global reach with capability to activate sites in underrepresented regions
- Regulatory strategy experience with EMA, FDA, and PMDA orphan drug applications
Compare Rare Disease CROs
Browse Clinical Vendor Compare's independent directory of 650+ vendors. Filter by specialist CRO category, therapeutic expertise, and geography to find the right partner for your rare disease programme.